The use of melittin to enhance transgene expression mediated by recombinant adeno-associated virus serotype 2 vectors both in vitro and in vivo

被引:0
|
作者
Yi-lin Xie [1 ]
Ji-yao Wang [1 ,2 ,3 ]
Yun He [1 ]
Xiao-min Yu [2 ,3 ]
Qing-yun Zheng [1 ]
Chen Ling [1 ,2 ,3 ]
Xi-lin Feng [1 ,4 ]
Li-qing Zhu [2 ,3 ]
机构
[1] State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology (Ministry of Education), School of Life Sciences, Zhongshan Hospital, Fudan University
[2] Department of Clinical Laboratory, the First Affiliated Hospital of Wenzhou Medical University
[3] Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province  4. Yantai Fuheng Biological Technology Co., Ltd.
基金
中国国家自然科学基金;
关键词
D O I
暂无
中图分类号
Q78 [基因工程(遗传工程)];
学科分类号
071007 ; 0836 ; 090102 ;
摘要
Objective: Melittin, a cell-penetrating peptide, improves the efficiency of many non-viral gene delivery vectors, yet its application in viral vectors has not been well studied. The non-pathogenic recombinant adeno-associated virus(rAAV) vector is an ideal in vivo gene delivery vector. However, its full potential will only be achieved after improvement of its transduction efficiency. To improve the transduction efficiency of rAAV2 vectors, we attempted to develop a melittin-based r AAV2 vector delivery strategy.Methods: The melittin peptide was inserted into the rAAV2 capsid either in the loop Ⅷ of all viral proteins(VPs) or at the N terminus of VP2. Various r AAV2-gfp or-fluc vectors were subjected to quantitative real-time polymerase chain reaction and Western blot assays to determine their titers and integrity of capsid proteins, respectively. Alternatively, the vectors based on wild-type capsid were pre-incubated with melittin, followed by transduction of cultured cells or tail vein administration of the mixture to C57BL/6 and BALB/c nude mice. In vivo bioluminescence imaging was performed to evaluate the transgene expression.Results: rAAV2 vectors with melittin peptide inserted in the loop Ⅷ of VPs had low transduction efficiency, probably due to dramatically reduced ability to bind to the target cells. Fusing the melittin peptide at the N-terminus of VP2 produced vectors without the VP2 subunit. Interestingly, among the commonly used rAAV vectors, pre-incubation of r AAV2 and rAAV6 vectors with melittin significantly enhanced their transduction efficiency in HEK293 and Huh7 cells in vitro. Melittin also had the ability to increase the rAAV2-mediated transgene expression in mouse liver in vivo. Mechanistically, melittin did not change the vector-receptor interaction. Moreover, cell counting kit-8 assays of cultured cells and serum transaminase levels indicated melittin had little cytotoxicity.Conclusion: Pre-incubation with melittin, but not insertion of melittin into the rAAV2 capsid, significantly enhanced rAAV2-mediated transgene expression. Although further in vivo evaluations are required, this research not only expands the pharmacological potential of melittin, but also provides a new strategy to improve gene therapy mediated by rAAV vectors.
引用
收藏
页码:106 / 116
页数:11
相关论文
共 50 条
  • [31] Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors
    Lam, P
    Hui, KM
    Wang, YM
    Allen, PD
    Louis, DN
    Yuan, CJ
    Breakefield, XO
    HUMAN GENE THERAPY, 2002, 13 (18) : 2147 - 2159
  • [32] Synthesis of human globin polypeptides mediated by recombinant adeno-associated virus vectors
    Ohi, S
    Kim, BC
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (03) : 274 - 281
  • [33] Recombinant adeno-associated virus vectors for gene therapy
    Conlon, TJ
    Flotte, TR
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) : 1093 - 1101
  • [34] Intracellular transport of recombinant adeno-associated virus vectors
    M Nonnenmacher
    T Weber
    Gene Therapy, 2012, 19 : 649 - 658
  • [35] Intracellular transport of recombinant adeno-associated virus vectors
    Nonnenmacher, M.
    Weber, T.
    GENE THERAPY, 2012, 19 (06) : 649 - 658
  • [36] Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo
    Zhong, L
    Li, W
    Yang, Z
    Chen, L
    Li, Y
    Qing, K
    Weigel-Kelley, KA
    Yoder, MC
    Shou, W
    Srivastava, A
    GENE THERAPY, 2004, 11 (14) : 1165 - 1169
  • [37] Gene therapy: Recombinant adeno-associated virus vectors
    Smith-Arica J.R.
    Bartlett J.S.
    Current Cardiology Reports, 2001, 3 (1) : 43 - 49
  • [38] Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo
    L Zhong
    W Li
    Z Yang
    L Chen
    Y Li
    K Qing
    K A Weigel-Kelley
    M C Yoder
    W Shou
    A Srivastava
    Gene Therapy, 2004, 11 : 1165 - 1169
  • [39] Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo
    Zhong, L
    Li, WM
    Yang, ZC
    Chen, LY
    Li, YJ
    Qing, KY
    Weigel-Kelley, KA
    Yoder, MC
    Shou, WN
    Srivastava, A
    MOLECULAR THERAPY, 2004, 9 : S376 - S376
  • [40] Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo
    Pacak, Christina A.
    Mah, Cathryn S.
    Thattaliyath, Bijoy D.
    Conlon, Thomas J.
    Lewis, Melissa A.
    Cloutier, Denise E.
    Zolotukhin, Irene
    Tarantal, Alice F.
    Byrne, Barry J.
    CIRCULATION RESEARCH, 2006, 99 (04) : E3 - E9